ArticleJournal of endocrinological investigation2026
Circulating 1,5-anhydroglucitol levels combined with pre-pregnancy BMI is a simple predictive marker of future glucose intolerance in women with gestational diabetes.
Article in Journal of endocrinological investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIn women with gestational diabetes (GDM), 1,5-Anhydroglucitol (1,5-AG) levels are lower compared to controls. However, data on 1,5-AG changes in the postpartum and its associations with indices of insulin secretion or resistance in the perinatal period are lacking. This prospective study assessed the trajectory of 1,5-AG, 1,5-AG/HOMA-IR and 1,5-AG/BMI during pregnancy up to 1-year postpartum, their association with indices of insulin secretion/resistance and whether these indices can predict glucose intolerance (prediabetes and diabetes) at 1-year postpartum in women with GDM.
methodsWe included 211 women with GDM and assessed 1,5-AG levels at 28–32 weeks of gestational age, at 6–8 weeks and at 1-year postpartum. In the context of changing body mass and insulin resistance, we also investigated 1,5-AG/BMI and 1,5-AG/HOMA-IR to adjust for prevailing BMI and HOMA-IR.
resultsCirculating 1,5-AG levels and 1,5-AG/BMI were stable between pregnancy and 6–8 weeks postpartum but increased at 1-year postpartum (p < 0.001). 1,5-AG/HOMA-IR increased between pregnancy and the early postpartum and stabilized at 1-year postpartum (p < 0.001). In the perinatal period, 1,5-AG/HOMA-IR was related to a higher insulin-resistance adjusted insulin secretion index (ISSI-2), lower BMI and higher MATSUDA (all p ≤ 0.001). 1,5-AG/pre-pregnancy BMI during pregnancy and 1,5-AG/HOMA-IR at 6–8 weeks postpartum (both p ≤ 0.024) predicted a lower risk of glucose intolerance at 1-year postpartum, the latter remained significant after adjusting for HbA1c.
conclusionsThese results suggest that 1,5-AG/HOMA-IR and 1,5-AG/pre-pregnancy BMI change in the perinatal period. They could provide useful information and may serve as markers of future glucose intolerance, and for early risk stratification in women after GDM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.